Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • Michael L. Altshuler
    Member
    • Nov 2007
    • 14

    #1

    Singles only

    In contrast to multifactorial diseases, the genetic basis of many monogenic disorders is firmly established. It is published, summarized and explained on paper or in highly regarded databases such as a series of reviews in http://www.genetests.org/ (recently moved to the NCBI bookshelf, http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene ).

    There are thousands of recognized single gene (monogenic) disorders. Their cumulative incidence is roughly 1%.

    Also, the penetrance is usually very high with single gene disorders. So must be the clinical validity or predictive value of the DNA tests.

    The new-generation methods of DNA sequencing or, for that matter, chip genotyping could probably be capable of detecting all single-gene disease mutations listed in the Genetests reviews over single run. Conceivably, in the clinical diagnostics setting the computer-annotated sequence data should be examined and verified by a qualified physician.

    Thus, the rapid comprehensive analysis of the genes implicated in single-gene genetic disorders appears to be feasible.

    Does anybody do that? If not, what is the matter?
  • ECO
    --Site Admin--
    • Oct 2007
    • 1360

    #2
    Michael,

    This post did not make any sense where you put it, so I've moved it here. If you had another destination in mind, let me know.

    -=ECO

    Comment

    • dcfargo
      Member
      • Aug 2008
      • 22

      #3
      Seems like a custom SNP-Chip would pass the FDA/CLIA more readily.

      Comment

      Latest Articles

      Collapse

      • SEQadmin2
        Multiomic Liquid Biopsy: What DNA/RNA Panels Reveal That DNA Alone Can’t
        by SEQadmin2



        Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?

        Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating
        ...
        10-14-2026, 09:55 AM
      • SEQadmin2
        New Genomics Technologies Take Aim at Long-Standing Limits
        by SEQadmin2


        Researchers using sequencing and genomics tools often have to make trade-offs. They can choose between speed or scale, short reads or long-range information, or targeted panels or a view of the whole transcriptome. New technologies that have been released this year are built to address those tough choices.

        We asked six companies the same four questions to learn about their latest products. The new technologies bring a lot to the table, including rethinking sequencing
        ...
        09-28-2026, 10:25 AM

      ad_right_rmr

      Collapse

      News

      Collapse

      Topics Statistics Last Post
      Started by SEQadmin2, Yesterday, 11:13 AM
      0 responses
      17 views
      0 reactions
      Last Post SEQadmin2  
      Started by SEQadmin2, Yesterday, 10:48 AM
      0 responses
      18 views
      0 reactions
      Last Post SEQadmin2  
      Started by SEQadmin2, 10-15-2026, 10:52 AM
      0 responses
      36 views
      0 reactions
      Last Post SEQadmin2  
      Started by SEQadmin2, 10-14-2026, 05:39 AM
      0 responses
      42 views
      0 reactions
      Last Post SEQadmin2  
      Working...